Skip to main content

Table 1 Clinical characteristics of the 65 examined patients with WD

From: Comparative assessment of clinical rating scales in Wilson’s disease

  N Percentage Median Range
Gender
 Female 33 50.8   
 Male 32 49.2   
Age at assessment (yr)
 All    35 15–62
 Female    40 15–62
 Male    29.5 16–62
Age at onset of symptoms (yr)    16 1–47
Age at time of diagnosis (yr)    17 3–54
Initial mode of manifestation
 Hepatic 46 70.8   
 Hepatic + neurological 10 15.4   
 Neurological 6 9.2   
 Asymptomatic 3 4.6   
Liver cirrhosis at time of diagnosis 21 32.3   
By initial mode of manifestation
  Hepatic [n = 46] 15 32.6   
  Hepatic + neurological [n = 10] 6 60.0   
Liver status at assessment
 MELD score [missing data n = 4]    7.3 6–17
 Child-Pugh score [missing data n = 7]    5 5–11
KFR at time of diagnosis [missing data n = 8] 28 49.1   
KFR at assessment 19 29.2   
Treatment at assessment in all patients (n = 65)
 D-Penicillamine 38 58.5   
 Trientine 16 24.6   
 Zinc 7 10.8   
 D-Penicillamine + zinc 2 3.1   
 Trientine + zinc 2 3.1   
Treatment at assessment in neurologically symptomatic patients (n = 16)
 Chelating agents 13 81.2   
 Zinc with or without chelating agent 3 18.8   
Duration of treatment (yr)    15 0.4–47
  1. Abbreviations: KFR Kayser-Fleischer ring, pts. patients, yr. years